Anti-NKG2D (NN8555)

:Inflammation - Crohn's disease
:Phase 2

A recombinant human monoclonal antibody. The compound's novel mechanism of action is intended to improve treatment outcomes in patients who do not respond adequately to existing treatments. A phase 2b programme is on-going. Note, to be approved in January; will not start p2b until 2015.

Company announcements
No company announcements matching the search criteria

Press releases
Novo Nordisk and Innate Pharma swap product rights (06 Oct 2008)
Read more press releases

Scientific abstracts

No scientific abstracts matching the search criteria

You can search for more clinical trials on